Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Bristol-Myers Squibb Company is placed third among them.

Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical leader in oncology, immunology, cardiovascular disease, and fibrosis, is undergoing major strategic changes as it adapts to shifting market conditions.

On September 17, 2025, the company announced plans to divest its 60% stake in a pharmaceutical joint venture in China. The move reflects a broader realignment as BMY joins other drugmakers in reducing exposure to China amid economic headwinds and supply chain challenges.

The divestiture comes alongside a $2.5 billion restructuring plan launched in 2023 aimed at cutting costs and driving efficiency. The program, expected to yield $2 billion in annual savings by 2027, involves reshaping R&D, commercial, and manufacturing operations. Workforce reductions are a key component, with 282 layoffs in New Jersey scheduled between December 2025 and March 2026. In total, the firm expects to save about $3.5 billion through multiple rounds of staff reductions and operational improvements.

Financially, Bristol-Myers Squibb Company (NYSE:BMY) will report Q3 2025 results on October 30, with analysts projecting earnings of $1.65 per share. BMY also reaffirmed shareholder returns, declaring a quarterly dividend of $0.62 per share on September 17.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.